Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Aileron Presents Proof-of-Concept Clinical Data for ALRN-6924 in Late-Breaking Presentation at EORTC-NCI-AACR Symposium
Transforming the Experience of Chemotherapy for Patients
Learn More
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
March 4, 2021
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global LifeĀ Sciences Conference
March 2, 2021
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical TrialĀ of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
January 11, 2021
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
More News